Description

Scientific leader with deep bioanalytical and biomarker expertise, accountable for building capabilities, shaping the strategic direction for bioanalytical and biomarker development and implementation, and ensuring timely, compliant delivery of PK, immunogenicity, and biomarker data for clinical trials in China. Serves as an expert across one or more technologies (e.g., immunoassays, cell-based assays, flow cytometry, LC-MS/MS, and genomics) and partners closely within TB&B and with cross-functional stakeholders (e.g., QPTS, Translational Medicine, Clinical Sciences, GRA) to advance clinical assets. Applies fit-for-purpose, context-of-use, and relevant regulatory principles to assay and biomarker strategies that enable timely, high-quality portfolio decisions.